Status:
RECRUITING
Modulating Movement Intention Via Cortical Stimulation
Lead Sponsor:
NYU Langone Health
Conditions:
Seizures
Seizure Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These resul...
Detailed Description
This study will: * Explore effects of TMS and tDCS on movement intention. * Discern the neural activity underlying modulation of movement intention with neuroimaging recording. * Identify brain stimu...
Eligibility Criteria
Inclusion
- (Healthy Controls)
- Fluent in English
- (Patients with PMD or PNES):
- Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
- Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening
Exclusion
- Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
- Chronic or progressive medical condition
- Any history of traumatic brain injury or significant head trauma
- Currently meets criteria for substance abuse or dependence
- History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
- Pregnancy
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
- Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
- Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
- Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
- PMD and PNES Patients
- Any history of traumatic brain injury or significant head trauma
- Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
- Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
- Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
- Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
- Recurrent visual hallucinations, within the past 6 months;
- History of significant uncontrollable movements of the head;
- Any clinically significant abnormality on vital signs
Key Trial Info
Start Date :
July 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03233399
Start Date
July 20 2017
End Date
May 1 2027
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016